Sudarshan Pharma Industries disclosed that its proposal to acquire a 9.50% equity stake in Med Therapy Biotechnology Inc., USA, remains under due diligence. The company confirmed that the transaction awaits confirmation from Med Therapy’s Board of Directors and the passage of necessary resolutions.

Acquisition Status

The Mumbai-based pharma firm issued a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This update follows a previous communication dated September 5, 2026, regarding the potential investment in the US-based biotechnology entity.

Sudarshan Pharma clarified that the proposal has been intimated to stakeholders but is not yet finalized. The company expects to provide further updates at the earliest possible time once the due diligence process concludes and regulatory approvals are secured.

Promoter Interest

The filing also addressed parallel proposals by the company’s promoters. Hemal Mehta, Chairman and Managing Director, and Sachin Mehta, Joint Managing Director, intend to acquire 1.50% each of Med Therapy’s equity shares.

These individual acquisitions are similarly subject to due diligence and pending board decisions from Med Therapy Biotechnology Inc. Sudarshan Pharma emphasized that these promoter-level deals are distinct from the corporate acquisition but follow the same procedural timeline.

Regulatory Compliance

The update was signed by Hemal Mehta on September 15, 2026. The company requested stock exchanges to record the status of these pending transactions. No financial figures or valuation details were disclosed for the proposed stakes.

Sudarshan Pharma Industries disclosed the release of a pledge on 2,00,000 equity shares held by its promoter, Mr. Hemal Mehta. The release was executed on August 6, 2026.

The company submitted the revised disclosure to BSE Limited on September 9, 2026, in compliance with Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing serves as an intimation regarding the removal of encumbrance from the promoter's holding.

Pledge Release Details

The pledged shares were originally encumbered to secure a loan taken by Mr. Mehta for personal reasons. The release of the pledge reduces the number of shares held under lien by the promoter.

Mr. Mehta currently holds 6,40,21,020 equity shares in Sudarshan Pharma Industries, representing 26.60% of the total share capital. The disclosure does not specify the remaining number of pledged shares following this release, nor does it detail the specific entity in whose favor the shares were previously encumbered.

The company's compliance officer, Nirav Shah, signed the intimation letter addressed to the Listing Department of BSE Limited. The filing references an earlier email from the exchange dated September 4, 2026, requesting the revised disclosure.